StockTipsArenaBeta

BUY Biocon Ltd — Swati Hotkar, Nirmal Bang Securities

BUYBiocon Ltd
Biocon share price target & all analyst calls

bySwati Hotkar, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))14 Jul 2026via NDTV Profit

Entry₹420Stated
Target₹460
Total upside +9.52% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Swati Hotkar for new calls(14% target hit, 50 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 27 Jul 2026
6 supporting0 opposing
Supports the BUY call (6)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Jul · today

5 advisors have active short-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·24 Jul · 3d ago

Eternal shares may receive up to $650 million in inflows led by this positive trigger

NewsCnbc-Tv18·22 Jul · 5d ago

(opens in new tab)

Biocon's Malaysia facility gets European regulator approval for new drug product fill finish for insulin

NewsCnbc-Tv18·16 Jul · 2w ago

(opens in new tab)

Kiran Mazumdar-Shaw says Biocon succession is in place, bets on India's biopharma boom

NewsCnbc-Tv18·15 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Swati Hotkar, Nirmal Bang Securities

Every call and its outcome